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tively. The anti-logged residuals of MAOI group were positively
skewed (skewness = 11.71). MAOI cases had greater costs than
controls ($3866) when the mean smearing estimator was used.
However, employing the median smearing estimator decreased
cost difference to $385, and provided a better model ﬁt (mean:
MSE = 3.80 ¥ 108; median: MSE = 1.19 ¥ 107). For modeling
costs of anti-coagulant DDI cohorts, skewness of anti-logged
residuals in controls was 28.44 as compared to 11.60 for cases.
Consequently, retransformed costs of controls were exaggerated
and had greater expenditures by $6674 when the mean smear-
ing estimator was employed. Conversely, using the median
smearing estimator, cases had greater costs by $216, and the
model ﬁt was better (mean: MSE = 3.04 ¥ 108; median: MSE =
2.41 ¥ 107). CONCLUSION: In this study, employment of the
median instead of the mean smearing estimator provided a better
ﬁtting model and was more accurate in predicting expenditures.
The results also suggest researchers should examine the distrib-
ution of anti-logged residuals when using the smearing 
retransformation.
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OBJECTIVES: To demonstrate how to use a life annuity to 
calculate medical costs for a cost-effectiveness analysis, and why
researchers should use this method. METHOD: A cost-
effectiveness analysis typically requires a single value to repre-
sent annual medical costs over time. While a straight average of
claims over several years of claims data seems to be a common
method to obtain this estimate, the value needed for the analy-
sis is more accurately calculated using the actuarial concept of a
life annuity. A life annuity is a series of payments (or costs) made
at equal intervals while a given life survives. The researcher cre-
ating a model that includes future annual medical claims needs
to take into account both the future value of the claim dollars
with discounting, and the likelihood that a person will live to
need medical claims each year with the probability of survival.
Once this “annuitized” claim cost is created, it is ready to be
used in a model where the relevant factors—discounting and sur-
vival—are present. This presentation will demonstrate the how
to calculate an annuitized claim cost using medical claims data
from MedStat’s MarketScan database. RESULTS: This demon-
stration will show proper use of discounting, survivorship, and
exposure in the calculation of this value. CONCLUSIONS: This
will be followed by several simpliﬁed models to show how the
resulting annuitized claim cost behaves in a cost-effectiveness
model compared to an actual stream of claim costs, and com-
pared to a claim cost based on a straight average of claims.
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OBJECTIVE: For most telephone-based nurse interventions, the
assumption of constant marginal and average personnel costs is
unrealistic. In spite of this fact, researchers frequently report
nursing personnel costs as simple functions of wage rates and
hours worked. In order to better forecast personnel costs, it is
necessary to understand learning and scale effects involving the
cumulative volumes of questions, encounters, and patients. For
an ongoing telephonic blood pressure intervention, we provide
summary statistics and regression output concerning learning
curve effects and economies of scale. METHODS: Using data on
personnel costs and cumulative production from the intervention
“Take Control of Your Blood Pressure,” we obtain least squares
estimates for learning curve elasticities. We include separate
terms in our regression to identify the elasticities of unit costs
with respect to 1) the cumulative volume of patient-speciﬁc
encounters; 2) the cumulative volume of speciﬁc questions; and
3) the cumulative volume of speciﬁc questions for speciﬁc
patients. In addition, we assess alternative returns-to-scale based
on Nerlove’s classic method. RESULTS: The elasticity of per-
sonnel cost is signiﬁcantly negative with respect to the cumula-
tive volume of speciﬁc questions (p = 0.036), and with respect
to the patient-speciﬁc cumulative volume of speciﬁc questions (p
= 0.001). Regarding patient-speciﬁc encounters, there is mixed
evidence concerning learning curve effects and economies of
scale. CONCLUSION: To forecast personnel costs in telephone-
based nursing interventions, it is important to account for learn-
ing curve effects. Including only wage rates and patient grand
means will result in an overestimation of costs. To a signiﬁcant
extent, unit costs decline systematically as cumulative output
rises.
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Drug plan decision makers need accurate ﬁnancial impact pro-
jections for planning new drug policies. Projections should have
minimal margins of error and be transparent and easy to com-
municate to stakeholders. OBJECTIVES: We explain how ad hoc
methods typically used for ﬁnancial impact projections are inad-
equate. METHODS: We describe a ﬂexible tool for projecting
the ﬁnancial impact of drug policy changes based on historical
dispensing data. The tool uses a random sample of a drug plan’s
beneﬁciaries to simulate the drug claim adjudication process
under the proposed policy regulations. We explore the validity
of the simulation tool using a recent example of a complex drug
policy change in British Columbia (BC). Over 500 different
policy options were simulated in the planning phase of the BC
policy. Drug plan spending was projected for each option before
the ﬁnal policy was selected two months prior to the policy start.
RESULTS: Predicted future total spending for the chosen policy
option was within 1% of actual spending in the ﬁrst 11 months
($555.8M and $560.0M, respectively). The average difference
per week between actual and predicted amounts was 0.015%
($86,500, SD: $968,700). CONCLUSIONS: Such policy simu-
lation can be applied to a wide range of health plans and policy
changes.
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OBJECTIVES: Drug plan decision makers make choices of con-
siderable ﬁnancial impact in short periods of time. To reduce
